GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (FRA:0L8) » Definitions » EV-to-FCF

Lantheus Holdings (FRA:0L8) EV-to-FCF : 19.27 (As of May. 15, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Lantheus Holdings's Enterprise Value is €4,961 Mil. Lantheus Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €257 Mil. Therefore, Lantheus Holdings's EV-to-FCF for today is 19.27.

The historical rank and industry rank for Lantheus Holdings's EV-to-FCF or its related term are showing as below:

FRA:0L8' s EV-to-FCF Range Over the Past 10 Years
Min: -432.55   Med: 21.97   Max: 433.41
Current: 19.03

During the past 13 years, the highest EV-to-FCF of Lantheus Holdings was 433.41. The lowest was -432.55. And the median was 21.97.

FRA:0L8's EV-to-FCF is ranked better than
57.72% of 518 companies
in the Drug Manufacturers industry
Industry Median: 24.625 vs FRA:0L8: 19.03

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-15), Lantheus Holdings's stock price is €71.66. Lantheus Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €6.058. Therefore, Lantheus Holdings's PE Ratio for today is 11.83.


Lantheus Holdings EV-to-FCF Historical Data

The historical data trend for Lantheus Holdings's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings EV-to-FCF Chart

Lantheus Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.54 269.87 49.07 13.70 16.05

Lantheus Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.17 24.21 18.37 16.05 15.13

Competitive Comparison of Lantheus Holdings's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lantheus Holdings's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Lantheus Holdings's EV-to-FCF falls into.



Lantheus Holdings EV-to-FCF Calculation

Lantheus Holdings's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=4960.570/257.377
=19.27

Lantheus Holdings's current Enterprise Value is €4,961 Mil.
Lantheus Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €257 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lantheus Holdings  (FRA:0L8) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Lantheus Holdings's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=71.66/6.058
=11.83

Lantheus Holdings's share price for today is €71.66.
Lantheus Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.058.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Lantheus Holdings EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Lantheus Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Lantheus Holdings (FRA:0L8) Business Description

Traded in Other Exchanges
Address
201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Lantheus Holdings (FRA:0L8) Headlines

No Headlines